---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-007474"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:48:17.753430+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Virios Therapeutics Q1 net loss $1.3M; Long-COVID study enrollment >50%

## Summary
- Net loss $1.3M ($0.07/shr) vs $1.5M ($0.08/shr) in Q1 2023; cash $2.4M at March 31, 2024.
- R&D expenses $0.3M (down from $0.5M); G&A expenses $1.0M (down from $1.1M).
- BHC Long-COVID phase 2 trial (IMC-2) exceeded 50% enrollment; top-line data expected H2 2024.
- Preliminary safety shows IMC-2 well tolerated; no serious adverse events reported to date.
- Global patent for IMC-2 covering Long-COVID and Alzheimer's published; FM partner discussions ongoing.

## SEC filing metadata
- accession: 0001558370-24-007474
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837024007474/0001558370-24-007474-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837024007474/viri-20240509x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-007474
- JSON: https://secwatch.observer/filing/0001558370-24-007474.json
- Plain text: https://secwatch.observer/filing/0001558370-24-007474.txt

## Key facts
- Earnings Releases
  Dogwood Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income $1.3 million, EPS $0.07 basic and diluted net loss per share.
  - Period: the first quarter ended March 31, 2024
  - Net income: $1.3 million
  - EPS: $0.07 basic and diluted net loss per share
  - Result: reported results
  source text: Virios Therapeutics, Inc. (the “Company”) issued a press release announcing the results of operations for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818844/000155837024007474/0001558370-24-007474-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.